Journal: Bioengineered

Article Title: AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.

doi: 10.1080/21655979.2021.2001238

Figure Lengend Snippet: Figure 6. JAK1 overexpression abolishes effects of AZD3759 on clone formation and DNA damage in RA-treated PC-9 cells. (a) Effects of AZD3759 and osimertinib on RTK pathway activity are evaluated using the RTK signaling antibody array. (b) Transfection efficacy is confirmed using Western blotting assay. (c) Survival fraction is determined after PC-9 cells or JAK1-overexpressing PC-9 cells are treated with different concentrations of AZD3759 (*p < 0.05 vs. control, **p < 0.01 vs. control). (d) DNA damage is evaluated using the γ-H2AX immunofluorescence assay (**p < 0.01 vs. RA, ##p < 0.01 vs. AZD3759 + RA). JAK, Janus kinase 1; RA, radiation; RTK, receptor tyrosine kinase.

Article Snippet: Receptor tyrosine kinase signaling antibody array[19] The PathScan RTK Signaling Antibody Array Kit (CST, Boston, USA) which contained 39 antibodies was used to evaluate the effects of osimertinib and AZD3759 on the phosphorylated forms of receptor tyrosine kinases (RTKs) or key signaling proteins.

Techniques: Over Expression, Activity Assay, Ab Array, Transfection, Western Blot, Control, Immunofluorescence